NAVIGATE
News
$400,000 program extends AST-004 into another major CNS indication and reinforces the breadth of its cerebroprotective potential Groton, CT – August 25, 2026 – Astrocyte
Groton, CT, June 17, 2025 – Astrocyte Pharmaceuticals Inc., a clinical-stage biotechnology company today announced two major milestones that could change the way we protect
August 19, 2024 HARTFORD–U.S. Senator Chris Murphy (D-Conn.) on Monday announced that Astrocyte Pharmaceuticals, a Groton-based clinical-stage biopharmaceuticals company, was named “Innovator of the Month” for
Green Light for Phase 2 Trial of AST-004 in Acute Ischemic Stroke Patients Groton, CT, March 12, 2024 – Astrocyte Pharmaceuticals Inc., a clinical-stage biopharmaceutical
Groton, CT, August 18, 2023 – Astrocyte Pharmaceuticals Inc., a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries,
Groton, CT, April 10, 2023 – Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries,
Groton, CT, April 5, 2023 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is
Groton, CT, September 14, 2022 – Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries,
Groton, CT, June 15, 2022 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced
Groton, CT, December 14, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company developing novel cerebroprotective therapeutics for patients with brain injuries, announced
Groton, CT, November 22, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries,
Groton, CT, September 16, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain